Evidence map›Paper›PMID 35113351›Full record

SynthesisInfection2022

Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness.

Jaffar A Al-Tawfiq, Thoyaja Koritala, Saad Alhumaid, Mazin Barry, Abeer N Alshukairi, Mohamad-Hani Temsah, Abbas Al Mutair, Ali Rabaan, Raghavendra Tirupathi, Philippe Gautret

Open access · bronzeAbstract readMeta-AnalysisReview
In one paragraph

Synthesis in Infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Molecular dynamics studies reveal structural and functional features of the SARS-CoV-2 spike protein.BioEssays : news and reviews in molecular, cellular and developmental biology · 2022
    Review
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 10 institutions in 7 countries.

Jaffar A Al-TawfiqInfectious Disease Unit, Specialty Internal Medicine, Dhahran Health Center, Johns Hopkins Aramco Healthcare, Rm A-420, Building 61, P.O. Box 76, Dhahran, 31311, Saudi Arabia. jaffar.tawfiq@jhah.com.ORCID http://orcid.org/0000-0002-5752-2235
Thoyaja KoritalaDepartment of Internal Medicine, Mayo Clinic Health System, Mankato, MN, USA.
Saad AlhumaidAministration of Pharmaceutical Care, Alahsa Health Cluster, Ministry of Health, Alahsa, Saudi Arabia.
Mazin BarryDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine, King Saud University and King Saud University Medical City, Riyadh, Saudi Arabia.
Abeer N AlshukairiDepartment of Medicine, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia.
Mohamad-Hani TemsahPediatric Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abbas Al MutairResearch Center, Almoosa Specialist Hospital, Alahsa, Saudi Arabia.
Ali RabaanMolecular Diagnostics Laboratory, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
Raghavendra TirupathiDepartment of Medicine Keystone Health, Penn State University School of Medicine, Hershey, PA, USA.
Philippe GautretAix Marseille Univ, IRD, AP-HM, SSA, VITROME, Marseille, France.
Aix-Marseille Université · FRJohns Hopkins University · USKing Faisal Specialist Hospital & Research Centre · SAKing Saud University · SAMayo Clinic Health System · USMinistry of Health · MMPennsylvania Chamber of Business and Industry · USPrincess Nourah bint Abdulrahman University · SASaudi Aramco Medical Services Organization · SAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCOVID-19 vaccines have been developed to compact the current SARS-CoV-2 pandemic and have been administered to people all over the world. These vaccines have been quite effective in reducing the possibility of severe illness, hospitalization and death. However, the recent emergence of Variants of Concern specifically the delta variant, B.1.617.2, had resulted in additional waves of the pandemic.

methodsWe aim to review the literature to understand the transmission and disease severity, and determine the efficacy of the current COVID-19 vaccines. We searched Pubmed, Scopus, and Embase till August 4th 2021, and used the search terms "delta variant", "vaccinations"," breakthrough infections", and "neutralizing antibody". For the meta-analysis, 21 studies were screened in particular and five articles (148,071 cases) were included in the study, and only four were analyzed in the meta-analysis.

resultsIn this review, both in vitro and in vivo studies showed significant reductions in neutralization rates against delta variants for vaccinated individuals and convalescent patients with prior history of COVID-19. However, There was a lower incidence of infection with SARS-CoV-2 due to Delta variant was found after the second dose of Pfizer-BioNTech, Oxford-AstraZeneca and Moderna vaccines.

conclusionIn fully vaccinated individuals, symptomatic infection with the delta variant was significantly reduced, and therefore, vaccinations play an important role to assist the fight against delta variant.

Indexed as

COVID-19SARS-CoV-2BNT162 VaccineCOVID-19 VaccinesHumansVaccine EfficacyBNT162 VaccineCOVID-19 VaccinesCOVID-19Delta variantSARS-CoV-2Variants

Identifiers

PMID35113351
PMCPMC8811010
OpenAlexW4210444958

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.